Adverse effects may also include minor side effects such as oily skin, acne, and seborrhea, as well as loss of scalp hair, which may be prevented or reduced with 5α-reductase inhibitors. In women,<unk> can produce hirsutism (excessive facial/body hair growth), deepening of the voice, and other signs of virilization. Exogenous<unk> may cause suppression of spermatogenesis in men, leading to, in some cases, reversible infertility. Gynecomastia and breast tenderness may occur with high dosages of<unk> due to peripheral conversion of<unk> by aromatase into excessive amounts of the estrogen estradiol.<unk> treatment, particularly in high dosages, can also be associated with mood changes, increased aggression, increased sex drive, spontaneous erections, and nocturnal emissions. Other side effects include increased hematocrit, which can require venipuncture in order to treat, and exacerbation of sleep apnea. The FDA stated in 2015 that neither the benefits nor the safety of<unk> have been established for low<unk> levels due to aging. The FDA has required that<unk> pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke. They have also required the label include concerns about abuse and dependence. Injectable forms of<unk> can cause a lung problem called pulmonary oil microembolism (POME). Symptoms of POME include cough, shortness of breath, tightening of the throat, chest pain, sweating, dizziness, and fainting. A postmarketing analysis by the manufacturer of Aveed<unk> undeconate injection) found that POME occurred at a rate of less than 1% per injection per year for Aveed. Long-term adverse effects Cardiovascular disease Adverse effects of<unk> supplementation may include increased cardiovascular events (including strokes and heart attacks) and deaths based on three peer-reviewed studies involving men taking<unk> replacement. In addition, an increase of 30% in deaths and heart attacks in older men has been reported. Due to an increased incidence of adverse cardiovascular events compared to a placebo group, a<unk> in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee. On January 31, 2014, reports of strokes, heart attacks, and deaths in men taking FDA-approved<unk> replacement led the FDA to announce that it would be investigating the issue. Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of<unk> Replacement Therapy (TRT). The FDA now requires warnings in the drug labeling of all approved<unk> products regarding deep vein thrombosis and pulmonary embolism. Up to the year 2010, studies had not shown any effect on the risk of death, prostate cancer or cardiovascular disease; more recent studies, however, do raise concerns. A 2013 study, published in the Journal of the American Medical Association, reported "the use of<unk> therapy was significantly associated with increased risk of adverse outcomes." The study began after a previous, randomized, clinical trial of<unk> therapy in men was stopped prematurely "due to adverse cardiovascular events raising concerns about<unk> therapy safety." Prostate cancer<unk> in the presence of a slow-growing prostate cancer is assumed to increase its growth rate. However, the association between<unk> supplementation and the development of prostate cancer is unproven. Nevertheless, physicians are cautioned about the cancer risk associated with<unk> supplementation. It may accelerate pre-existing prostate cancer growth in individuals who have undergone androgen deprivation. It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy. Ethnic groups have different rates of prostate cancer. Differences in sex hormones, including<unk>  have been suggested as an explanation for these differences. This apparent paradox can be resolved by noting that prostate cancer is very common. In autopsies, 80% of 80-year-old men have prostate cancer. Pregnancy and breastfeeding<unk> is contraindicated in pregnancy and not recommended during breastfeeding. Androgens like<unk> are teratogens and are known to cause fetal harm, such as producing virilization and ambiguous genitalia.
Testosterone 
Counterregulatory hormone
Menotropin
Luteinizing hormone
Orexin
Adrenocortical hormone
Androgen
Adrenalone